Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Pomalyst
Pomalidomide is an immunomodulatory drug (IMiD) used in the treatment of multiple myeloma. It works by modulating the immune system and inhibiting the growth of myeloma cells. It is structurally similar to thalidomide and lenalidomide, but with increased potency and a different side effect profile. Pomalidomide is generally used in patients who have relapsed or become resistant to other myeloma treatments.
For the treatment of multiple myeloma in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Pomalidomide is a derivative of thalidomide. It can cause severe life-threatening birth defects. Must not be used in pregnancy. Female patients must comply with the Pomalyst REMS Program.
Most likely new formulation: Combination therapy with other novel agents (Year: 2025, 75% confidence)
Based on clinical trial data and post-market surveillance, pomalidomide has a high likelihood (80%) of remaining a key treatment option for relapsed/refractory multiple myeloma.
Immunomodulatory Agent, Antineoplastic Agent
Glutarimide derivative